"Your Calendar Is Leaking Revenue" — How SkipUp's AI Agent Kills Scheduling Forever

"Your Calendar Is Leaking Revenue" — How SkipUp's AI Agent Kills Scheduling Forever

Every company has a scheduling problem. Most just don't know how expensive it is. The coordination tax on mid-market companies runs up to $4,500 per employee per year, and up to 70% of inbound leads never even make it to a booked meeting. In this episode, Superintelligence Editor-in-Chief Kim sits down with SkipUp co-founders Dheer and Sasha to unpack why scheduling is still fundamentally broken in 2026 and how their AI agent is replacing the entire back-and-forth. SkipUp doesn't send a booking link and wait. It lives inside your email thread, reads context, proposes times across calendars and time zones, follows up autonomously, and books the meeting. No forms, no friction, no lost deals. We talk about why traditional scheduling tools like Calendly hit a ceiling, how a two-person team built an email-native AI agent in months, the hidden revenue impact of every meeting that doesn't happen, and what work looks like when the coordination layer is fully automated.

Beyond LLMs: How Large Quantitative Models Are Curing Diseases and Reinventing Materials

LLMs predict the next word. LQMs predict the physical world. In this episode, Kim sits down with Nadia Harhen, General Manager of AI Simulation at SandboxAQ — a company that spun out of Google's Moonshot Factory, raised over $950 million, and counts NVIDIA and Google among its investors. Nadia explains what Large Quantitative Models (LQMs) are, how they differ from the LLMs we all know, and why they could be the key to inventing new drugs, designing next-generation batteries, and tackling problems like rare genetic diseases and environmental waste. We talk about her journey from bench scientist at Johnson & Johnson to clearing cutting-edge AI medical devices to leading one of the most ambitious AI simulation teams in the world. We discuss SandboxAQ's work with Aramco on turning waste into valuable materials, why no AI-designed drug has passed Phase II clinical trials yet, and what breakthroughs she expects in the next five years. If you think AI is just about chatbots and text generation, this episode will change your mind. Topics covered: — What are Large Quantitative Models (LQMs) and how do they work? — LQMs vs. LLMs: Why language models can't invent new drugs — SandboxAQ's origin inside Google's Moonshot Factory — Drug discovery, battery chemistry, and catalysis breakthroughs — The case for rare genetic diseases — Why NVIDIA and Google are betting big on this technology Guest: Nadia Harhen — GM of AI Simulation, SandboxAQ Previously: Google, Johnson & Johnson | Harvard Medical School

Inside Nemotron: NVIDIA’s Kari Briski on the Architecture Reshaping Enterprise AI

NVIDIA’s Kari Briski joins Kim Isenberg live from GTC 2026 to break down Nemotron 3 Super — a 120B parameter model with a hybrid Mamba-2/Transformer/MoE architecture, 1M token context, and 5x throughput gains. They go deep on what makes it different, why NVIDIA released the full training recipe, and what the new Nemotron Coalition signals about where enterprise AI is heading.